Famotidine Injection Rx
Generic Name and Formulations:
Famotidine 10mg/mL; soln for IV inj or infusion after dilution; multidose vials contain benzyl alcohol.
Various generic manufacturers
Indications for Famotidine Injection :
Hospitalized patients with pathological hypersecretory conditions, intractable ulcers, or as a short-term alternative to oral dosage forms.
Give by IV inj over 2 mins or infuse over 15–30 mins. 20mg every 12hrs.
See full labeling. Give by IV inj over 2 mins or infuse over 15 mins. <1yr: not recommended. 1–16yrs: initially 0.25mg/kg every 12hrs; max 40mg/day.
Moderate to severe renal insufficiency (CrCl <50mL/min): reduce to half the dose or prolong dosing interval to 36–48hrs. Pregnancy (Cat.B). Nursing mothers: not recommended.
May give antacids concomitantly.
Headache, dizziness, constipation, diarrhea, inj site reactions; rare: CNS reactions, prolonged QT interval in impaired renal function.
Formerly known under the brand name Pepcid Injection.
Tabs—30, 100; Susp—50mL; Inj—contact supplier
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight